EBS Emergent BioSolutions Inc.

Emergent BioSolutions to Participate in Upcoming Investor Conferences

Emergent BioSolutions to Participate in Upcoming Investor Conferences

GAITHERSBURG, Md., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the following investor conferences:

  • Wells Fargo 20th Annual Healthcare Conference

    September 4, 2025

    3:00 pm ET

    Webcast link One-on-one meetings
  • HCW 27th Annual Global Investment Conference

    September 9, 2025

    1:30 PM ET

    Webcast link One-on-one meetings

Please contact your conference representative to request one-on-one meetings.

Participants can view the presentations and replays by visiting the page of Emergent’s website.

About Emergent BioSolutions

At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threat, visit our  and follow us on , , ,  and .

Investor Contact:

Richard S. Lindahl

Executive Vice President, CFO

  

Media Contact:

Assal Hellmer

Vice President, Communications



EN
27/08/2025

Underlying

EBSEmergent BioSolutions Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Emergent BioSolutions Inc.

 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions to Participate in Upcoming Investor Conferences

Emergent BioSolutions to Participate in Upcoming Investor Conferences GAITHERSBURG, Md., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the following investor conferences: Wells Fargo 20th Annual Healthcare ConferenceSeptember 4, 20253:00 pm ETWebcast link One-on-one meetings HCW 27th Annual Global Investment ConferenceSeptember 9, 20251:30 PM ETWebcast link One-on-one meetings Please contact your conference representative to request one-on-one meetings. Participa...

8h / 24m 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Supports Voices for Awareness and Facing Fentany...

Emergent BioSolutions Supports Voices for Awareness and Facing Fentanyl Now on August 21, 2025 for National Fentanyl Prevention and Awareness Day™ GAITHERSBURG, Md., Aug. 21, 2025 (GLOBE NEWSWIRE) -- As opioid emergencies continue to be the leading cause of accidental death in the United States,1 Emergent BioSolutions (NYSE: EBS) is teaming up with Voices for Awareness and Facing Fentanyl Now in honor of National Fentanyl Prevention and Awareness Day™ on August 21, 2025. As part of this year’s efforts, these leading advocacy organizations and its sponsors will bring their message to Times...

August 21, 2025 1 EN
EBS Emergent BioSol...

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Emergent BioSolutions Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 14 August 2025 in which we reassessed the appropriateness of the ratings in the ...

EBS EMERGENT BIOSOLUTIONS INC.
08/18/25 August 18, 2025 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Reports Second Quarter 2025 Financial Results

Emergent BioSolutions Reports Second Quarter 2025 Financial Results Second Quarter 2025 Total Revenues of $140.9 million, above Q2 guidance by $21 millionSecond Quarter 2025 Net Loss of $12.0 million and Net Loss Margin of (9)%, an improvement of 96% and 10,200 bps, respectively, versus prior yearSecond Quarter 2025 Gross Margin % of 36% and Adjusted Gross Margin % of 49%, an expansion of 6,200 bps and 2,300 bps, respectively, versus prior yearSecond Quarter 2025 Adjusted EBITDA of $28.5 million, an increase of 382% versus prior yearSecond Quarter 2025 Adjusted EBITDA Margin of 20% of Total...

August 6, 2025 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

New Publication in Expert Review of Anti-infective Therapy Evaluates B...

New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox Ongoing mpox outbreak continues to be a global health threat and is driving need for greater therapeutic research and innovation GAITHERSBURG, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the publication of a comprehensive review article, "Brincidofovir in the Era of Mpox," in the peer-reviewed journal Expert Review of Anti-infective Therapy.1 This publication includes an overview of brincidofovir, in vitro and in v...

July 28, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch